Organon & Co. Target of Unusually Large Options Trading (NYSE:OGN)

06 Jan 2026, 10:42 by Jessica Moore · The Cerbat Gem

Organon & Co. (NYSE:OGN – Get Free Report) was the recipient of unusually large options trading on Tuesday. Stock investors bought 17,794 call options on the stock. This is an increase of 550% compared to the typical volume of 2,737 call options.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on OGN shares. Piper Sandler cut shares of Organon & Co. from an “overweight” rating to an “underweight” rating and set a $5.00 price objective for the company. in a research note on Monday, October 27th. Weiss Ratings reissued a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. JPMorgan Chase & Co. cut their price target on shares of Organon & Co. from $14.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, November 11th. Wall Street Zen raised Organon & Co. from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Morgan Stanley lowered their price objective on Organon & Co. from $10.00 to $9.00 and set an “equal weight” rating on the stock in a research note on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, two have issued a Hold rating and four have given a Sell rating to the company’s stock. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of “Reduce” and an average target price of $8.38.

View Our Latest Analysis on OGN

Organon & Co. Price Performance

Shares of Organon & Co. stock traded up $0.44 during mid-day trading on Tuesday, reaching $7.88. 1,710,009 shares of the stock were exchanged, compared to its average volume of 3,513,408. The company has a market cap of $2.05 billion, a price-to-earnings ratio of 4.10, a price-to-earnings-growth ratio of 1.50 and a beta of 0.58. The company has a current ratio of 1.75, a quick ratio of 1.20 and a debt-to-equity ratio of 9.69. The firm has a 50-day simple moving average of $7.17 and a 200 day simple moving average of $8.87. Organon & Co. has a fifty-two week low of $6.18 and a fifty-two week high of $17.23.

Organon & Co. (NYSE:OGN – Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported $1.01 EPS for the quarter, beating analysts’ consensus estimates of $0.93 by $0.08. The firm had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.57 billion. Organon & Co. had a net margin of 7.95% and a return on equity of 143.47%. During the same period in the previous year, the business earned $1.38 earnings per share. On average, sell-side analysts predict that Organon & Co. will post 3.68 EPS for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, December 11th. Stockholders of record on Thursday, November 20th were issued a $0.02 dividend. This represents a $0.08 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend was Thursday, November 20th. Organon & Co.’s payout ratio is presently 4.17%.

Institutional Investors Weigh In On Organon & Co.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada raised its position in Organon & Co. by 53.4% in the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock valued at $5,374,000 after purchasing an additional 125,648 shares during the last quarter. Amundi increased its stake in shares of Organon & Co. by 16.7% in the first quarter. Amundi now owns 719,105 shares of the company’s stock valued at $10,392,000 after buying an additional 102,715 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Organon & Co. by 870.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 1,010,789 shares of the company’s stock valued at $15,051,000 after buying an additional 906,675 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares in the last quarter. Finally, Fred Alger Management LLC acquired a new position in Organon & Co. during the 1st quarter worth about $267,000. 77.43% of the stock is owned by institutional investors and hedge funds.

Organon & Co. Company Profile

(Get Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.